Hepatitis C virus infection in Argentina: Burden of chronic disease

Autores
Ridruejo, Ezequiel; Bessone, Fernando; Daruich, Jorge R.; Estes, Chris; Gadano, Adrián Carlos; Razavi, Homie; Villamil, Federico; Silva, Marcelo Oscar
Año de publicación
2016
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
AIM: To estimate the progression of the hepatitis C virus (HCV) epidemic and measure the burden of HCVrelated morbidity and mortality. METHODS: Age- and gender-defined cohorts were used to follow the viremic population in Argentina and estimate HCV incidence, prevalence, hepatic complications, and mortality. The relative impact of two scenarios on HCV-related outcomes was assessed: (1) increased sustained virologic response (SVR); and (2) increased SVR and treatment. RESULTS: Under scenario 1, SVR raised to 85%-95% in 2016. Compared to the base case scenario, there was a 0.3% reduction in prevalent cases and liverrelated deaths by 2030. Given low treatment rates, cases of hepatocellular carcinoma and decompensated cirrhosis decreased < 1%, in contrast to the base case in 2030. Under scenario 2, the same increases in SVR were modeled, with gradual increases in the annual diagnosed and treated populations. This scenario decreased prevalent infections 45%, liver-related deaths 55%, liver cancer cases 60%, and decompensated cirrhosis 55%, as compared to the base case by 2030. CONCLUSION: In Argentina, cases of end stage liver disease and liver-related deaths due to HCV are still growing, while its prevalence is decreasing. Increasing in SVR rates is not enough, and increasing in the number of patients diagnosed and candidates for treatment is needed to reduce the HCV disease burden. Based on this scenario, strategies to increase diagnosis and treatment uptake must be developed to reduce HCV burden in Argentina.
Fil: Ridruejo, Ezequiel. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad Austral. Hospital Universitario Austral.; Argentina. Centro de Educaciones Médicas e Investigación Clínica "Norberto Quirno"; Argentina
Fil: Bessone, Fernando. Universidad Nacional de Rosario; Argentina
Fil: Daruich, Jorge R.. Universidad de Buenos Aires. Facultad de Medicina. Hospital de Clínicas General San Martín; Argentina
Fil: Estes, Chris. Center For Disease Analysis; Estados Unidos
Fil: Gadano, Adrián Carlos. Hospital Italiano; Argentina
Fil: Razavi, Homie. Center For Disease Analysis; Estados Unidos
Fil: Villamil, Federico. Hospital Británico de Buenos Aires; Argentina
Fil: Silva, Marcelo Oscar. Universidad Austral. Hospital Universitario Austral.; Argentina
Materia
ARGENTINA
DIAGNOSIS
DISEASE BURDEN
EPIDEMIOLOGY
HEPATITIS C
INCIDENCE
MORTALITY
PREVALENCE
TREATMENT
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/105873

id CONICETDig_de65973e104e7614ab57d3e704f9915b
oai_identifier_str oai:ri.conicet.gov.ar:11336/105873
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Hepatitis C virus infection in Argentina: Burden of chronic diseaseRidruejo, EzequielBessone, FernandoDaruich, Jorge R.Estes, ChrisGadano, Adrián CarlosRazavi, HomieVillamil, FedericoSilva, Marcelo OscarARGENTINADIAGNOSISDISEASE BURDENEPIDEMIOLOGYHEPATITIS CINCIDENCEMORTALITYPREVALENCETREATMENThttps://purl.org/becyt/ford/3.2https://purl.org/becyt/ford/3AIM: To estimate the progression of the hepatitis C virus (HCV) epidemic and measure the burden of HCVrelated morbidity and mortality. METHODS: Age- and gender-defined cohorts were used to follow the viremic population in Argentina and estimate HCV incidence, prevalence, hepatic complications, and mortality. The relative impact of two scenarios on HCV-related outcomes was assessed: (1) increased sustained virologic response (SVR); and (2) increased SVR and treatment. RESULTS: Under scenario 1, SVR raised to 85%-95% in 2016. Compared to the base case scenario, there was a 0.3% reduction in prevalent cases and liverrelated deaths by 2030. Given low treatment rates, cases of hepatocellular carcinoma and decompensated cirrhosis decreased < 1%, in contrast to the base case in 2030. Under scenario 2, the same increases in SVR were modeled, with gradual increases in the annual diagnosed and treated populations. This scenario decreased prevalent infections 45%, liver-related deaths 55%, liver cancer cases 60%, and decompensated cirrhosis 55%, as compared to the base case by 2030. CONCLUSION: In Argentina, cases of end stage liver disease and liver-related deaths due to HCV are still growing, while its prevalence is decreasing. Increasing in SVR rates is not enough, and increasing in the number of patients diagnosed and candidates for treatment is needed to reduce the HCV disease burden. Based on this scenario, strategies to increase diagnosis and treatment uptake must be developed to reduce HCV burden in Argentina.Fil: Ridruejo, Ezequiel. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad Austral. Hospital Universitario Austral.; Argentina. Centro de Educaciones Médicas e Investigación Clínica "Norberto Quirno"; ArgentinaFil: Bessone, Fernando. Universidad Nacional de Rosario; ArgentinaFil: Daruich, Jorge R.. Universidad de Buenos Aires. Facultad de Medicina. Hospital de Clínicas General San Martín; ArgentinaFil: Estes, Chris. Center For Disease Analysis; Estados UnidosFil: Gadano, Adrián Carlos. Hospital Italiano; ArgentinaFil: Razavi, Homie. Center For Disease Analysis; Estados UnidosFil: Villamil, Federico. Hospital Británico de Buenos Aires; ArgentinaFil: Silva, Marcelo Oscar. Universidad Austral. Hospital Universitario Austral.; ArgentinaBaishideng Publishing Group2016-05info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/105873Ridruejo, Ezequiel; Bessone, Fernando; Daruich, Jorge R.; Estes, Chris; Gadano, Adrián Carlos; et al.; Hepatitis C virus infection in Argentina: Burden of chronic disease; Baishideng Publishing Group; World Journal of Hepatology; 8; 15; 5-2016; 649-6581948-5182CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/doi/10.4254/wjh.v8.i15.649info:eu-repo/semantics/altIdentifier/url/https://www.wjgnet.com/1948-5182/full/v8/i15/649.htminfo:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-29T09:34:52Zoai:ri.conicet.gov.ar:11336/105873instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-29 09:34:52.749CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Hepatitis C virus infection in Argentina: Burden of chronic disease
title Hepatitis C virus infection in Argentina: Burden of chronic disease
spellingShingle Hepatitis C virus infection in Argentina: Burden of chronic disease
Ridruejo, Ezequiel
ARGENTINA
DIAGNOSIS
DISEASE BURDEN
EPIDEMIOLOGY
HEPATITIS C
INCIDENCE
MORTALITY
PREVALENCE
TREATMENT
title_short Hepatitis C virus infection in Argentina: Burden of chronic disease
title_full Hepatitis C virus infection in Argentina: Burden of chronic disease
title_fullStr Hepatitis C virus infection in Argentina: Burden of chronic disease
title_full_unstemmed Hepatitis C virus infection in Argentina: Burden of chronic disease
title_sort Hepatitis C virus infection in Argentina: Burden of chronic disease
dc.creator.none.fl_str_mv Ridruejo, Ezequiel
Bessone, Fernando
Daruich, Jorge R.
Estes, Chris
Gadano, Adrián Carlos
Razavi, Homie
Villamil, Federico
Silva, Marcelo Oscar
author Ridruejo, Ezequiel
author_facet Ridruejo, Ezequiel
Bessone, Fernando
Daruich, Jorge R.
Estes, Chris
Gadano, Adrián Carlos
Razavi, Homie
Villamil, Federico
Silva, Marcelo Oscar
author_role author
author2 Bessone, Fernando
Daruich, Jorge R.
Estes, Chris
Gadano, Adrián Carlos
Razavi, Homie
Villamil, Federico
Silva, Marcelo Oscar
author2_role author
author
author
author
author
author
author
dc.subject.none.fl_str_mv ARGENTINA
DIAGNOSIS
DISEASE BURDEN
EPIDEMIOLOGY
HEPATITIS C
INCIDENCE
MORTALITY
PREVALENCE
TREATMENT
topic ARGENTINA
DIAGNOSIS
DISEASE BURDEN
EPIDEMIOLOGY
HEPATITIS C
INCIDENCE
MORTALITY
PREVALENCE
TREATMENT
purl_subject.fl_str_mv https://purl.org/becyt/ford/3.2
https://purl.org/becyt/ford/3
dc.description.none.fl_txt_mv AIM: To estimate the progression of the hepatitis C virus (HCV) epidemic and measure the burden of HCVrelated morbidity and mortality. METHODS: Age- and gender-defined cohorts were used to follow the viremic population in Argentina and estimate HCV incidence, prevalence, hepatic complications, and mortality. The relative impact of two scenarios on HCV-related outcomes was assessed: (1) increased sustained virologic response (SVR); and (2) increased SVR and treatment. RESULTS: Under scenario 1, SVR raised to 85%-95% in 2016. Compared to the base case scenario, there was a 0.3% reduction in prevalent cases and liverrelated deaths by 2030. Given low treatment rates, cases of hepatocellular carcinoma and decompensated cirrhosis decreased < 1%, in contrast to the base case in 2030. Under scenario 2, the same increases in SVR were modeled, with gradual increases in the annual diagnosed and treated populations. This scenario decreased prevalent infections 45%, liver-related deaths 55%, liver cancer cases 60%, and decompensated cirrhosis 55%, as compared to the base case by 2030. CONCLUSION: In Argentina, cases of end stage liver disease and liver-related deaths due to HCV are still growing, while its prevalence is decreasing. Increasing in SVR rates is not enough, and increasing in the number of patients diagnosed and candidates for treatment is needed to reduce the HCV disease burden. Based on this scenario, strategies to increase diagnosis and treatment uptake must be developed to reduce HCV burden in Argentina.
Fil: Ridruejo, Ezequiel. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad Austral. Hospital Universitario Austral.; Argentina. Centro de Educaciones Médicas e Investigación Clínica "Norberto Quirno"; Argentina
Fil: Bessone, Fernando. Universidad Nacional de Rosario; Argentina
Fil: Daruich, Jorge R.. Universidad de Buenos Aires. Facultad de Medicina. Hospital de Clínicas General San Martín; Argentina
Fil: Estes, Chris. Center For Disease Analysis; Estados Unidos
Fil: Gadano, Adrián Carlos. Hospital Italiano; Argentina
Fil: Razavi, Homie. Center For Disease Analysis; Estados Unidos
Fil: Villamil, Federico. Hospital Británico de Buenos Aires; Argentina
Fil: Silva, Marcelo Oscar. Universidad Austral. Hospital Universitario Austral.; Argentina
description AIM: To estimate the progression of the hepatitis C virus (HCV) epidemic and measure the burden of HCVrelated morbidity and mortality. METHODS: Age- and gender-defined cohorts were used to follow the viremic population in Argentina and estimate HCV incidence, prevalence, hepatic complications, and mortality. The relative impact of two scenarios on HCV-related outcomes was assessed: (1) increased sustained virologic response (SVR); and (2) increased SVR and treatment. RESULTS: Under scenario 1, SVR raised to 85%-95% in 2016. Compared to the base case scenario, there was a 0.3% reduction in prevalent cases and liverrelated deaths by 2030. Given low treatment rates, cases of hepatocellular carcinoma and decompensated cirrhosis decreased < 1%, in contrast to the base case in 2030. Under scenario 2, the same increases in SVR were modeled, with gradual increases in the annual diagnosed and treated populations. This scenario decreased prevalent infections 45%, liver-related deaths 55%, liver cancer cases 60%, and decompensated cirrhosis 55%, as compared to the base case by 2030. CONCLUSION: In Argentina, cases of end stage liver disease and liver-related deaths due to HCV are still growing, while its prevalence is decreasing. Increasing in SVR rates is not enough, and increasing in the number of patients diagnosed and candidates for treatment is needed to reduce the HCV disease burden. Based on this scenario, strategies to increase diagnosis and treatment uptake must be developed to reduce HCV burden in Argentina.
publishDate 2016
dc.date.none.fl_str_mv 2016-05
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/105873
Ridruejo, Ezequiel; Bessone, Fernando; Daruich, Jorge R.; Estes, Chris; Gadano, Adrián Carlos; et al.; Hepatitis C virus infection in Argentina: Burden of chronic disease; Baishideng Publishing Group; World Journal of Hepatology; 8; 15; 5-2016; 649-658
1948-5182
CONICET Digital
CONICET
url http://hdl.handle.net/11336/105873
identifier_str_mv Ridruejo, Ezequiel; Bessone, Fernando; Daruich, Jorge R.; Estes, Chris; Gadano, Adrián Carlos; et al.; Hepatitis C virus infection in Argentina: Burden of chronic disease; Baishideng Publishing Group; World Journal of Hepatology; 8; 15; 5-2016; 649-658
1948-5182
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/doi/10.4254/wjh.v8.i15.649
info:eu-repo/semantics/altIdentifier/url/https://www.wjgnet.com/1948-5182/full/v8/i15/649.htm
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv Baishideng Publishing Group
publisher.none.fl_str_mv Baishideng Publishing Group
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1844613081549766656
score 13.070432